Low-dose PAX-101 improves autism spectrum disorder symptoms in boys
Boys with autism spectrum disorder who received 10 mg/kg of a suramin IV infusion known as PAX-101 experienced greater improvements in symptoms than those who received 20 mg/kg of the same treatment or placebo, data show.
PAX-101 (suramin IV, PaxMedica) is an antipurinergic therapy delivered once monthly via a “proprietary intranasal formulation,” according to the manufacturer. The therapy appears to reverse the effects of mitochondrial dysfunction, which has been hypothesized to be the cause of autism spectrum disorder symptoms, via purinergic receptor blockade. It may lower the amount of neuroinflammation in children, the manufacturer said.